e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Improving asthma therapy - new findings in established and experimental treatment modalities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Returning asthma symptoms correlate with free IgE upon omalizumab cessation
M. Humbert, P. Lowe, C. Ferioli, C. Martin, M. Blogg (Clamart, France; Basel, Switzerland; Horsham, United Kingdom)
Source:
Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Session:
Improving asthma therapy - new findings in established and experimental treatment modalities
Session type:
Thematic Poster Session
Number:
3639
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Humbert, P. Lowe, C. Ferioli, C. Martin, M. Blogg (Clamart, France; Basel, Switzerland; Horsham, United Kingdom). Returning asthma symptoms correlate with free IgE upon omalizumab cessation. Eur Respir J 2007; 30: Suppl. 51, 3639
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Free serum IgE suppression with omalizumab and clinical outcomes in asthma
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Omalizumab decreases IgE production in patients with severe allergic asthma
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Chlamydia pneumoniae
(Cp)-specific IgE is associated with asthma severity
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011
Is omalizumab response influenced by passive smoking in severe asthma?
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Year: 2018
Monitoring free serum IgE in severe asthma patients treated with omalizumab
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Monitoring free serum IgE in asthma patients treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Specific serum IgE is associated with seasonal symptom load in children with allergic rhinitis
Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis
Year: 2008
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 47s
Year: 2005
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma
Source: Eur Respir J 2002; 20: 1088-1094
Year: 2002
Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Improved symptom relief with omalizumab in the treatment of allergic rhinitis
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Evaluation of inhalant allergen-specific IgE in wheezing infants as predictor for persistent symptoms
Source: Annual Congress 2011 - Asthma: risk factors and comorbidities
Year: 2011
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept